Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Amazon Secures 200 MW Wind Power Deals in Sweden 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Toyota Global Sales Fall as China Demand Slumps 
France Targets Shein, Temu With Fast-Fashion Fees 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Add as a preferred source on Google
SAN DIEGO, March 28, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been chosen by Glycotope GmbH as a partner to accelerate their immuno-oncology drug discovery pipeline.
CrownBio offers the world’s largest collection of patient derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft cell line-derived cancer models as well as PDX models selected by Glycotope into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Glycotope’s innovative immuno-oncology drug discovery pipeline.
“Glycotope recognizes the value of CrownBio’s extensive PDX and CDX collection and their expertise in implementing innovative humanization strategies,” said Anika Jäkel, Director of Glycotope’s Preclinical Pharmacology & Cancer Immunology group. “We have chosen them as our partner for these reasons and look forward to what we are confident will be a successful alliance.”
“We are very pleased that Glycotope has selected us as a trusted partner to advance their cutting-edge immuno-oncology pipeline,” said Laurie Heilmann, CrownBio’s Chief Business Officer. “Our unique capabilities will enable Glycotope to continue providing new and improved therapies for the treatment of cancer.”
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
About Glycotope GmbH
Glycotope, founded in 2000 in Berlin, focuses on the development of innovative immuno-oncological products for the treatment of various cancer types using their GlycoBody and GlycoExpress® technologies. Glycotope has currently one product in clinical development. The Company’s additional pipeline includes preclinical antibody biopharmaceuticals for various oncological indications.
Glycotope’s GlycoExpress® (GEX®) platform allows glyco-optimization and high yield production of a variety of fully human glycosylated biopharmaceuticals such as antibodies, glycoprotein hormones and cytokines by using a toolbox of glyco-engineered proprietary human cell lines that allow for optimization of a whole series of different relevant sugars. In addition, the GEX® platform can be used for in process glycosylation control. Visit http://www.glycotope.com/.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
